Author:
Tsompos Constantinos,Panoulis Constantinos,Toutouzas Konstantinos,Zografos George,Papalois Apostolos
Abstract
The aim of this experimental study was to examine the effect of erythropoietin on rat model and particularly in an ischemia reperfusion (HR) protocol. The effect of that molecule was studied biochemically using blood mean glucose (Gl) levels. Materials and methods: 40 rats of mean weight 247.7 g were used in the study. Gl levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of reperfusion. Erythropoietin was administered only in groups C and D. Results were that Epo administration non-significantly increased the gl levels by 5.59% +6.46% (p=0.3208). Reperfusion time non-significantly increased the gl levels by 5.63%+6.45% (p=0.4098). However, erythropoietin administration and reperfusion time together produced a non significant combined effect in increasing the gl levels by 4.94%+3.81% (p= 0.1892). Conclusions: Results of this study indicate that erythropoietin administration, reperfusion time, or their interaction non-significantly increase the blood glucose levels in short-term. Opposite bibliographic data are considered more reliable, until a greater sample provide clearer results.
Reference16 articles.
1. Proteomic analysis to display the effect of low doses of erythropoietin on rat liver regeneration;Bader;Life Sci,2011
2. Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation;Berridge;Biochem J,1995
3. Pulse wave velocity is associated with early clinical outcome after ischemic stroke;Gąsecki;Atherosclerosis,2012
4. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models;Katz;J Endocrinol,2010
5. Kokot F, Nieszporek T, Wiecek A, Marcinkowski W, Rudka R, Trembecki J (1994). Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialysed patients. Nephrol Dial Transplant 9 Suppl 3, 35-39